xMedica

NCT05712200ClinicalTrials.gov

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision…

Phase 32,500 participants sought789 sites35 countries

Categories

Cardiovascular100%

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Registered after enrolment began (about 38 days after the recorded start)First posted 2023-02-03; recorded start 2022-12-27
  • Has a defined primary outcomeA primary outcome measure is listed in the record
  • The primary outcome states a time frameThe primary outcome measure records a time frame
  • Participants are randomly assignedAllocation is recorded as randomised
  • Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Uses blinding (masking)A masking level is recorded in the record
  • An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Sponsor has 7 other studies in this databaseCounted from the lead sponsor named in the record (Anthos Therapeutics, Inc.)
  • Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding13/20

    Double-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type7/10

    Clinical-event endpoint

  • Multi-centre8/8

    Multi-centre: 789 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration3/5

    Registered within 30 days of the study start

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,500 participants (target), run at 789 sites, across 35 countries.

How this score is built
  • Enrolment34/40

    2,500 participants (target)

  • Site count25/25

    789 sites

  • Country count15/15

    35 countries

  • Planned duration10/10

    Planned over about 61 months

  • Sponsor scale3/10

    Anthos Therapeutics, Inc. has led 8 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

Patients enrolled in the study are randomized in a 1:1 ratio to receive abelacimab 150 mg SC or matching placebo once monthly. The study is comprised of 3 periods: 1) screening period of up to 60 days, 2) an event-driven, double-blind treatment period (abelacimab 150 mg SC or matching placebo) completed after at least 111 patients have experienced an adjudicated primary endpoint event, and 3) EoT visit in core part followed by either (i) a 30-day follow-up period (EoS for core part) OR (ii) an optional OLE beginning at the EoT visit for eligible patients to receive open-label abelacimab treatment. The optional extension will only be offered to patients following regulatory and ethics approval in participating countries.

Conditions

  • Atrial Fibrillation (AF)

Eligibility

SexAll
Ages65 Years – No maximum
Healthy volunteersNo

Eligibility as written in the registry

Inclusion Criteria: * Patient is able to understand and has provided written informed consent to participate in the trial * Diagnosed Atrial Fibrillation (AF) or atrial flutter (documented on an electrocardiogram (ECG) or monitor recording) * Age 65-74 and a CHA2DS2VASc ≥4 OR age ≥75 and a CHA2DS2VASc ≥3 * Patient is judged by the responsible physician to be unsuitable for oral anticoagulation because the risks outweigh the benefits or the patient is unwilling to take oral anticoagulation AND this determination was made prior to and independent of the study * At least 1 bleeding risk factor such as severe renal insufficiency, planned daily use of antiplatelet medication for the duration of the trial, history of bleeding from a critical area, or other conditions associated with increased risk of bleeding such as chronic nonsteroidal anti-inflammatory drug (NSAID) use, frailty or multiple falls * Patient is judged by the responsible physician to be unsuitable for left atrial appendage (LAA) closure or occlusion device, an approved device is not available, or the patient is unwilling to undergo the procedure AND this determination was made prior to and independent of the study Exclusion Criteria: * AF due to an ongoing acute reversible cause (e.g., cardiac surgery, pulmonary embolism (PE), untreated hyperthyroidism, alcohol use) * Patients who within 60 days prior to randomization (1) received a vitamin K antagonists (VKA) (e.g., warfarin, phenprocoumon, acenocoumarol) or a direct oral anticoagulant (DOAC) such as, dabigatran, rivaroxaban, apixaban, or edoxaban or (2) were newly diagnosed with AF * Patients with an intracranial or intraocular bleed within the 3 months prior to screening or any history of spontaneous intracerebral hemorrhage at any time in the absence of antithrombotic treatment * Any stroke within 14 days before randomization or transient ischemic attack (TIA) within 3 days before randomization * Mechanical heart valve or valve disease that is expected to require mechanical valve replacement intervention (surgical or invasive) during the course of the study * Patients on dialysis at screening or who are planned to start dialysis within 6 months Other protocol defined Inclusion/Exclusion criteria may apply

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study typeInterventional
PhasePhase 3
AllocationRandomised
Intervention modelPARALLEL
Primary purposeTREATMENT
MaskingDOUBLE (2)
Enrolment2,500 participants sought

Sponsor and collaborators

  • Anthos Therapeutics, Inc. Sponsor
  • Novartis Pharmaceuticals Collaborators

Arms and interventions

  • Abelacimab (MAA868)EXPERIMENTAL

    Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.

  • PlaceboPLACEBO_COMPARATOR

    Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.

Interventions

  • Biological Abelacimab

    Abelacimab provided as liquid in vial (150 mg/mL)

  • Drug Placebo

    Dosage Formulation: Liquid (in vial) Dose Strength: Placebo to Abelacimab

Outcome measures

  1. Primary outcome

    Efficacy: Time to first event of ischemic stroke or systemic embolism (SE)

    Undetermined strokes will be counted as ischemic strokes

    Time frame Up to 30 months

  2. Primary outcome

    Safety: Time to first occurrence of Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding

    Time frame Up to 30 months

  3. Secondary outcome

    Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), or acute limb ischemia

    Abelacimab versus placebo with regard to the composite of ischemic stroke, SE, MI, VTE, or acute limb ischemia

    Time frame Up to 30 months

  4. Secondary outcome

    Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), or Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding event

    Time frame Up to 30 months

  5. Secondary outcome

    Efficacy: Cardiovascular (CV) mortality

    Time frame Up to 30 months

  6. Secondary outcome

    Efficacy: All-cause mortality

    Time frame Up to 30 months

  7. Secondary outcome

    Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), acute limb ischemia, or International Society on Thrombosis and Haemostasis (ISTH) major bleeding

    Abelacimab versus placebo with regard to net clinical outcome defined as the composite of ischemic stroke, SE, MI, VTE, acute limb ischemia, or International Society on Thrombosis and Haemostasis (ISTH) major bleeding

    Time frame Up to 30 months

Dates

Start dateDecember 27, 2022 (actual)
Primary completionDecember 30, 2027 (estimated)
CompletionDecember 30, 2027 (estimated)
First postedFebruary 3, 2023 (actual)
Last updatedJuly 13, 2026
Results postedNot stated in the registry record
Status last verifiedJuly 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

645 sites are recruiting

Argentina

FacilityCityState or regionStatus
Anthos Investigational site 1400Bahía BlancaBuenos AiresRecruiting
Anthos Investigative Site 1430Buenos AiresRecruiting
Anthos Investigative Site 1411Buenos AiresRecruiting
Anthos Investigational site 1446Buenos AiresBuenos Aires F.D.Recruiting
Anthos Investigational site 1443Buenos AiresBuenos Aires F.D.Recruiting
Anthos Investigative Site 1409Ciudad Autónoma Buenos AiresRecruiting
Anthos Investigative Site 1410Ciudad Autónoma de Buenos AireRecruiting
Anthos Investigative Site 1423Ciudad Autónoma de Buenos AireRecruiting
Anthos Investigational site 1441CiudadelaBuenos AiresRecruiting
Anthos Investigative Site 1429Coronel SuárezRecruiting
Anthos Investigative Site 1420CorrientesRecruiting
Anthos Investigative Site 1431CórdobaRecruiting
Anthos Investigative Site 1407CórdobaRecruiting
Anthos Investigative Site 1418CórdobaRecruiting
Anthos Investigational site 1444CórdobaCórdoba ProvinceRecruiting
Anthos Investigative Site 1424CórdobaRecruiting
Anthos Investigative Site 1414CórdobaRecruiting
Anthos Investigative Site 1427CórdobaRecruiting
Anthos Investigative Site 1434CórdobaRecruiting
Anthos Investigative Site 1419CórdobaRecruiting
Anthos Investigational site 1438La PlataBuenos AiresRecruiting
Anthos Investigative Site 1402La PlataRecruiting
Anthos Investigative Site 1417QuilmesRecruiting
Anthos Investigative Site 1415Ramos MejíaRecruiting
Anthos Investigational site 1452SaltaSalta ProvinceRecruiting
Anthos Investigative Site 1403SaltaRecruiting
Anthos Investigative Site 1425San LuisRecruiting
Anthos Investigative Site 1426San MartinRecruiting
Anthos Investigational site 1449San Miguel de TucumánTucumán ProvinceRecruiting
Anthos Investigational site 1451San Miguel de TucumánRecruiting
Anthos Investigative Site 1435San Miguel de TucumánRecruiting
Anthos Investigative Site 1404San Miguel de TucumánRecruiting
Anthos Investigative Site 1436San NicolásRecruiting
Anthos Investigational site 1445TemperleyBuenos AiresRecruiting
Anthos Investigational site 1439Villa MaríaCórdoba ProvinceRecruiting

Brazil

FacilityCityState or regionStatus
Anthos Investigative Site 1518AracajuRecruiting
Anthos Investigative Site 1516Belo HorizonteWithdrawn
Anthos Investigative Site 1507Belo HorizonteRecruiting
Anthos Investigative Site 1527Belo HorizonteRecruiting
Anthos Investigative Site 1528Belo HorizonteRecruiting
Anthos Investigative Site 1513BlumenauRecruiting
Anthos Investigative Site 1505BlumenauRecruiting
Anthos Investigative Site 1535BrasíliaRecruiting
Anthos Investigative Site 1501Campina Grande do SulRecruiting
Anthos Investigative Site 1522CampinasRecruiting
Anthos Investigative Site 1503CampinasWithdrawn
Anthos Investigative Site 1520Campo GrandeRecruiting
Anthos Investigative Site 1532CanoasRecruiting
Anthos Investigative Site 1526Caxias do SulRecruiting
Anthos Investigative Site 1542ColatinaRecruiting

739 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

No changes have been recorded since we first ingested this record.

A change is recorded each time the sponsor updates the registry record. Status, dates, enrolment and sites appear here as they move.

Registry: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT05712200